Estimation of radiation dose to patients from (18) FDG whole body PET/CT investigations using dynamic PET scan protocol

Aruna Kaushik, Abhinav Jaimini, Madhavi Tripathi, Maria D'Souza, Rajnish Sharma, Anupam Mondal, Anil K Mishra, Bilikere S Dwarakanath, Aruna Kaushik, Abhinav Jaimini, Madhavi Tripathi, Maria D'Souza, Rajnish Sharma, Anupam Mondal, Anil K Mishra, Bilikere S Dwarakanath

Abstract

Background & objectives: There is a growing concern over the radiation exposure of patients from undergoing 18FDG PET/CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) whole body investigations. The aim of the present study was to study the kinetics of 18FDG distributions and estimate the radiation dose received by patients undergoing 18FDG whole body PET/CT investigations.

Methods: Dynamic PET scans in different regions of the body were performed in 49 patients so as to measure percentage uptake of 18FDG in brain, liver, spleen, adrenals, kidneys and stomach. The residence time in these organs was calculated and radiation dose was estimated using OLINDA software. The radiation dose from the CT component was computed using the software CT-Expo and measured using computed tomography dose index (CTDI) phantom and ionization chamber. As per the clinical protocol, the patients were refrained from eating and drinking for a minimum period of 4 h prior to the study.

Results: The estimated residence time in males was 0.196 h (brain), 0.09 h (liver), 0.007 h (spleen), 0.0006 h (adrenals), 0.013 h (kidneys) and 0.005 h (stomach) whereas it was 0.189 h (brain), 0.11 h (liver), 0.01 h (spleen), 0.0007 h (adrenals), 0.02 h (kidneys) and 0.004 h (stomach) in females. The effective dose was found to be 0.020 mSv/MBq in males and 0.025 mSv/MBq in females from internally administered 18FDG and 6.8 mSv in males and 7.9 mSv in females from the CT component. For an administered activity of 370 MBq of 18FDG, the effective dose from PET/CT investigations was estimated to be 14.2 mSv in males and 17.2 mSv in females.

Interpretation & conclusions: The present results did not demonstrate significant difference in the kinetics of 18FDG distribution in male and female patients. The estimated PET/CT doses were found to be higher than many other conventional diagnostic radiology examinations suggesting that all efforts should be made to clinically justify and carefully weigh the risk-benefit ratios prior to every 18FDG whole body PET/CT scan.

Conflict of interest statement

Conflicts of Interest: None.

Figures

Fig. 1
Fig. 1
Representative time activity curves depicting the uptake of activity in adult male and female brain.
Fig. a and 2b
Fig. a and 2b
Time activity curves normalized to the administered activity for adult males (2a) and females (2b) liver, spleen and adrenals.
Fig. 3a and 3b
Fig. 3a and 3b
Time activity curves normalized to the administered activity for adult males (3a) and females (3b) kidneys and stomach.

References

    1. Brix G, Lechel U, Glatting G, Ziegler SI, Munzing W, Muller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality [18] F-FDG PET/CT examinations. J Nucl Med. 2005;46:608–13.
    1. Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166–74.
    1. Towson JEC, Eberl S. Radiation protection and dosimetry in PET and PET/CT. In: Valk PE, Delbeke D, Bailey DL, Townsend DW, Maisey MN, editors. Positron emission tomography. London: Springer; 2006. pp. 41–62.
    1. Radiation protection in newer medical imaging techniques: PET/CT. Safety Reports Series No. 58. Vienna, Austria: IAEA; 2008. International Atomic Energy Agency (IAEA)
    1. Sources – Report to the General Assembly, Scientific Annexes A and B. Vienna, Austria: UNSCEAR; 2008. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Vol. 1.
    1. Gallagher BM, Ansari A, Atkins H, Casella V, Christman DR, Fowler JS, et al. Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med. 1977;18:990–6.
    1. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44:127–37.
    1. Reivich M, Alavi A, Greenberg J, Farkas T, Wolf A. [18F]fluorodeoxyglucose method for measuring local cerebral glucose metabolism in man: technique and results. Prog Nucl Med. 1981;7:138–48.
    1. Brownell GL, Ackerman RH, Strauss HW, Elmaleh DR, Cochavi S, Alpert N, et al. Preliminary imaging results with 18F-2-fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr. 1980;4:473–7.
    1. Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M. The radiation dosimetry of 2-[18F]fluoro-2-deoxy-D-glucose in man. J Nucl Med. 1982;23:613–7.
    1. Smith T. Re: The radiation dosimetry of 2.[18F] fluoro-2-deoxy-D-glucose in man. J Nucl Med. 1983;24:447–8.
    1. International Commission on Radiological Protection (ICRP). Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann ICRP. 1988;18:1–4.
    1. Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med. 1991;32:699–706.
    1. Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1998;25:565–74.
    1. Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Yamadera A, Itoh M. Internal absorbed dose estimation by a TLD method for [18] F-FDG and comparison with the dose estimates from whole body PET. Phys Med Biol. 1999;44:595–606.
    1. International Commission on Radiological Protection (ICRP). Radiation dose to patients from radiopharmaceuticals (Addendum 2 to ICRP Publication 53) Ann ICRP. 1998;28(3):1–126. ICRP Publication 80. Canada: ICRP; 1998.
    1. Hays MT, Segall GM. A mathematical model for the distribution of fluorodeoxyglucose in humans. J Nucl Med. 1999;40:1358–66.
    1. Niven E, Thompson M, Nahmias C. Absorbed dose to the adult male and female brain from 18F-fluorodeoxyglucose. Health Phys. 2001;80:62–6.
    1. Hays MT, Watson EE, Thomas SR, Stabin M. MIRD dose estimate report no.19: radiation absorbed dose estimates from [18] F-FDG. J Nucl Med. 2002;43:210–4.
    1. Chang KP, Liu CY, Lin YH, Chang PJ, Lee YK, Shao CH. Assessment of absorbed dose of PET (18F-FDG) scanning patients with MIRD and TLD methods. Ann Nucl Med. 2007;20:137–43.
    1. International Commission on Radiological Protection (ICRP). Radiation dose to patients from radiopharmaceuticals - addendum 3 to ICRP Publication 53. ICRP Publication 106. Ann ICRP. 2008;38:1–2.
    1. Khamwan K, Krisanachinda A, Pasawang P. The determination of patient dose from 18F-FDG PET/CT examination. Radiat Prot Dosimetry. 2010;141:50–5.
    1. Kaushik A, Jaimini A, Tripathi M, D’souza M, Sharma R, Mishra AK, et al. Estimation of patient dose in 18F-FDG and 18F-FDOPA PET/CT examinations. J Cancer Res Ther. 2013;9:477–83.
    1. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16. Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(Suppl 2):37S–61S.
    1. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol. 1980;238:E69–82.
    1. Smith EM. Calculating absorbed doses from radiopharmaceuticals. Nucleonics. 1966;24:33–9. 68.
    1. Report on the task group on reference man. ICRP Publication 23 Ottawa, Canada: ICRP; 1975. International Commission on Radiological Protection (ICRP)
    1. Tissue substitutes in radiation dosimetry and measurement. ICRU Report 44. Bethesda, Md., USA: ICRU; 1989. International Commission on Radiation Units and Measurements (ICRU)
    1. Stabin MG. Health concerns related to radiation exposure of the female nuclear medicine patient. Environ Health Perspect. 1997;105(Suppl 6):1403–9.
    1. Tanaka G, Kawamura H, Nakahara Y. Reference Japanese man - 1 Mass of organs and other characteristics of normal Japanese. Health Phys. 1979;36:333–46.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj